Skip to main
CODX

Co-Diagnostics (CODX) Stock Forecast & Price Target

Co-Diagnostics (CODX) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Co-Diagnostics Inc is experiencing growth prospects in the respiratory infectious disease diagnostics market, particularly influenced by significant investments in Saudi Arabia, which is expected to enhance its operational reach. The company's strategic partnership with Arabian Eagle Manufacturing through the joint venture CoMira Diagnostics will facilitate the development, distribution, and commercialization of its innovative Co-Dx technologies across 18 MENA nations. Additionally, Co-Diagnostics is advancing its proprietary sample preparation instrument aimed at reducing costs for PCR testing, while also pursuing regulatory approvals for enhancements to its COVID-19 testing, underscoring its commitment to expanding access to affordable diagnostics.

Bears say

Co-Diagnostics, Inc. faces significant risks that negatively impact its financial outlook, including potential failures in clinical evaluations and the inability to secure necessary regulatory clearances, which could hinder commercial success amid a competitive landscape. The company reported a modest revenue of $145,000 for the third quarter of 2025 while incurring a substantial net loss of $5.9 million, translating to a loss of $0.16 per share. Additionally, concerns regarding the dilution risk associated with future fundraising efforts, which may come with less favorable terms, further exacerbate the bleak financial perspective for the company.

Co-Diagnostics (CODX) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Co-Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Co-Diagnostics (CODX) Forecast

Analysts have given Co-Diagnostics (CODX) a Buy based on their latest research and market trends.

According to 3 analysts, Co-Diagnostics (CODX) has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Co-Diagnostics (CODX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.